WHO Issues Interim Recommendations for Moderna COVID-19 Vaccine

The World Health Organization (WHO) has issued interim recommendations for the use of Moderna's COVID-19 vaccine, mRNA-1273, in individuals aged 18 and above. The guidance addresses key aspects such as who should receive the vaccine, its safety profile, dosage, and efficacy across different population groups.

According to the WHO's Strategic Advisory Group of Experts on Immunization (SAGE), healthcare workers and the elderly are recommended for priority vaccination, similar to other COVID-19 vaccines. As vaccine availability increases, other groups disproportionately affected by COVID-19 and facing health inequities should also be prioritized.

Individuals with comorbid conditions, including chronic lung disease, heart conditions, severe obesity, diabetes, liver disease, and HIV infection, are also recommended for vaccination due to their increased risk of severe COVID-19. The vaccine is recommended for pregnant women when the benefits of vaccination outweigh potential risks. Breastfeeding should not be a reason to discontinue vaccination.

The Moderna vaccine is not recommended for individuals under 18 years of age or those with a history of severe allergic reaction to any of its components. SAGE recommends a two-dose schedule of 100 µg, administered 28 days apart, with a possible extension to 42 days. The vaccine has demonstrated an efficacy of approximately 94.1% against COVID-19, with protection beginning 14 days after the first dose.

Moderna's vaccine received Emergency Use Listing (EUL) from the WHO on April 30th, following a thorough review of its quality, safety, and efficacy. The European Medicines Agency (EMA) has also authorized its use within the European Union. Long-term safety is subject to ongoing monitoring through clinical trials and post-marketing surveillance.